胃癌是全世界癌症死亡的第四大主要原因，术前准确的分期对胃癌患者后期选择治疗策略起到至关重要的作用。随着超声内镜(EUS)、多层螺旋CT、MRI等影像学技术的发展，胃癌临床分期的准确率已得到明显改善。多项研究表明血清学标记物，包括血浆纤维蛋白原水平、中性粒细胞/淋巴细胞比值(NLR)、血小板/淋巴细胞比值(PLR)等与胃癌患者术前分期及治疗效果有关，将血清学标记物纳入胃癌分期评估可使术前分期更加准确，为肿瘤个体化治疗提供更好的依据。本文旨在对胃癌分期评估模型的发展研究现状与展望作一综述。

Gastric cancer is the fourth leading cause of cancer death in the world, and accurate preoperative staging plays a crucial role in the later selection of treatment strategies for gastric cancer patients.With the development of endoscopic ultrasonography (EUS), multi-slice spiral CT, MRI and other imaging techniques, the accuracy of clinical staging of gastric cancer has been significantly improved.Many studies have shown that serological markers, including plasma fibrinogen level, neutrophil/lymphocyte ratio (NLR), and platelet/lymphocyte ratio (PLR), are related to preoperative staging and therapeutic effect of patients with gastric cancer. The inclusion of serological markers in the staging assessment of gastric cancer can make preoperative staging more accurate and provide a better basis for individualized tumor treatment.This article aims to review the current status and prospects of the development of staging evaluation models for gastric cancer.